What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Myocardial infarction
- Cardiology
Sabina A. Murphy mainly investigates Internal medicine, Cardiology, Myocardial infarction, TIMI and Surgery.
Her Internal medicine study frequently draws connections between adjacent fields such as Diabetes mellitus.
Her Myocardial infarction study integrates concerns from other disciplines, such as Stroke, Platelet aggregation inhibitor and Hazard ratio.
In her research on the topic of Hazard ratio, Management of acute coronary syndrome is strongly related with Ticagrelor.
Her TIMI research incorporates elements of Ischemia, Atorvastatin and Pravastatin.
Her Surgery research is multidisciplinary, incorporating elements of Disease and Renal function.
Her most cited work include:
- Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes (5080 citations)
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2469 citations)
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2469 citations)
What are the main themes of her work throughout her whole career to date?
Sabina A. Murphy mostly deals with Internal medicine, Cardiology, TIMI, Myocardial infarction and Acute coronary syndrome.
Her work in the fields of Internal medicine, such as Stroke, ST elevation and Percutaneous coronary intervention, intersects with other areas such as In patient.
Her study involves Angina, Heart failure, Clopidogrel, Conventional PCI and Coronary artery disease, a branch of Cardiology.
Her TIMI study combines topics from a wide range of disciplines, such as Anesthesia, Vorapaxar, Diabetes mellitus, Fibrinolysis and Atrial fibrillation.
Her Myocardial infarction study incorporates themes from Aspirin and Hazard ratio.
The concepts of her Acute coronary syndrome study are interwoven with issues in Troponin, Troponin I, Atorvastatin and Pravastatin.
She most often published in these fields:
- Internal medicine (95.81%)
- Cardiology (79.60%)
- TIMI (58.65%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (95.81%)
- Cardiology (79.60%)
- TIMI (58.65%)
In recent papers she was focusing on the following fields of study:
Sabina A. Murphy spends much of her time researching Internal medicine, Cardiology, TIMI, Dapagliflozin and Myocardial infarction.
Her work in the fields of Internal medicine, such as Stroke and Hazard ratio, overlaps with other areas such as Evolocumab, In patient and PCSK9.
Her biological study spans a wide range of topics, including Albuminuria, Lorcaserin, Weight loss and Atrial fibrillation.
Sabina A. Murphy has included themes like Absolute risk reduction and Heart failure in her Dapagliflozin study.
Her study connects Rate ratio and Myocardial infarction.
Sabina A. Murphy interconnects Biomarker and Clopidogrel in the investigation of issues within Acute coronary syndrome.
Between 2017 and 2021, her most popular works were:
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (268 citations)
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. (263 citations)
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. (238 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Cardiology
Sabina A. Murphy focuses on Internal medicine, Cardiology, Evolocumab, Myocardial infarction and PCSK9.
The Stroke research Sabina A. Murphy does as part of her general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
Sabina A. Murphy works in the field of Cardiology, focusing on TIMI in particular.
Her TIMI research incorporates themes from Obesity and Atrial fibrillation.
Sabina A. Murphy is interested in Ticagrelor, which is a branch of Myocardial infarction.
Sabina A. Murphy has researched Unstable angina in several fields, including Absolute risk reduction and C-reactive protein.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
